- Home
- VTLE vs NVAX Comparison
VTLE vs NVAX Comparison
Compare VTLE & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- NVAX
- Stock Information
- Founded
- VTLE 2006
- NVAX 1987
- Country
- VTLE United States
- NVAX United States
- Employees
- VTLE N/A
- NVAX N/A
- Industry
- VTLE
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTLE
- NVAX Health Care
- Exchange
- VTLE Nasdaq
- NVAX Nasdaq
- Market Cap
- VTLE 1.3B
- NVAX 1.3B
- IPO Year
- VTLE 2011
- NVAX 1995
- Fundamental
- Price
- VTLE $28.76
- NVAX $7.99
- Analyst Decision
- VTLE Hold
- NVAX Buy
- Analyst Count
- VTLE 9
- NVAX 6
- Target Price
- VTLE $43.71
- NVAX $17.83
- AVG Volume (30 Days)
- VTLE 869.2K
- NVAX 3.6M
- Earning Date
- VTLE 02-19-2025
- NVAX 02-27-2025
- Dividend Yield
- VTLE N/A
- NVAX N/A
- EPS Growth
- VTLE N/A
- NVAX N/A
- EPS
- VTLE N/A
- NVAX N/A
- Revenue
- VTLE $1,952,314,000.00
- NVAX $885,193,000.00
- Revenue This Year
- VTLE $30.46
- NVAX N/A
- Revenue Next Year
- VTLE $7.38
- NVAX N/A
- P/E Ratio
- VTLE N/A
- NVAX N/A
- Revenue Growth
- VTLE 26.15
- NVAX N/A
- 52 Week Low
- VTLE $25.85
- NVAX $3.81
- 52 Week High
- VTLE $58.30
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- VTLE 34.54
- NVAX 42.04
- Support Level
- VTLE $32.83
- NVAX $7.70
- Resistance Level
- VTLE $35.92
- NVAX $8.54
- Average True Range (ATR)
- VTLE 1.64
- NVAX 0.39
- MACD
- VTLE -0.36
- NVAX -0.04
- Stochastic Oscillator
- VTLE 2.59
- NVAX 23.58
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.